Browse Articles
Discover research articles across all indexed journals
Long-term outcomes of neoadjuvant chemotherapy (NAC) before bladder-sparing chemoradiotherapy (CRT) for patients with nonmetastatic muscle-invasive bladder cancer (MIBC).
819 Background: Neoadjuvant cisplatin-based combination chemotherapy followed by concurrent chemoradiation is an emerging approach in carefully selected MIBC patients who opt for bladder sparing however, long-term data on its efficacy and tolerability remains lacking. We evaluated long-term outcomes in MIBC patients treated with this approach. Methods: We conducted a retrospective chart review of patients treated with NAC followed by CRT bladder sparing approaches between 2008 and 2017 at the Princess Margaret Cancer Centre and Lakeridge Health Cancer Centers. We initially published the feasibility of this approach and early outcome data in 2018. In this analysis, we updated long-term disease free survival (DFS), bladder intact disease free survival (BI-DFS) and overall survival (OS). Results: In total 57 patients were treated with NAC + CRT. Most were male with a median age of 72 (range 45-87), and an Eastern Cooperative Oncology Group performance status of 0 (60%) or 1 (40%). Patients with stage II (65%), and stage III disease (25%), as well as regional nodal metastases (11%), carcinoma in situ (28%) and hydronephrosis (25%) were included. The majority of patients completed planned NAC (95%). All patients completed external-beam radiotherapy, and 84% completed at least 60% of the planned concurrent weekly cisplatin doses. Median follow up for this population was 74.4 months (9.7-142.1). At the time of this updated analysis, 23/57 (40%) recurred, local recurrence occurred in 11/57 patients (19%), and 9/57 patients (16%) required salvage cystectomy. Distant recurrence occurred in 12/57 (21%) patients, all of whom died as a result of bladder cancer. The median DFS for the study population was 56.7 months (95% CI 25.3-99.1), and 5-year DFS rate was 49%. The median BI-DFS was 40.1 months (95% CI 23.3-85.4) and 5-year BI-DFS rate was 45%. The median OS was 104.9 months (95% CI 60.8-119.2) with a 5-year OS rate of 65% (95% CI 50.7-75.5). Conclusions: NAC+CRT is a safe and effective approach for selected patients with MIBC with encouraging long-term outcomes. This data supports evaluating neoadjuvant and adjuvant systemic therapies along with bladder preservation strategies in prospective clinical trials.
Metastasis-directed radiotherapy in oligometastatic bladder and upper tract cancer: A single institution retrospective experience.
799 Background: Metastasis-directed therapy (MDT) for oligometastatic cancer is a concept utilized for prostate and kidney cancer. Clinical research in MDT for oligometastatic urothelial carcinoma (UC) remains sparse especially in the modern era where systemic therapy advancements have substantially improved patient’s outcomes overall. We explored our institutional experience of patients with oligometastatic carcinoma of the bladder and upper tract undergoing MDT utilizing radiotherapy (RT). Methods: Patients were retrospectively identified with oligometastatic bladder or upper tract cancer from January 2016 to July 2024 with five or less sites of metastases. Those with equivalent dose of RT (EQD2 10 ) ≥ 45Gy to metastases were included. Progression free survival (PFS) and overall survival (OS) were evaluated using Kaplan Meier from time of diagnosis to metastatic disease. Cox proportional hazards analysis was conducted to determine covariates associated with survival endpoints. Results: 60 patients with oligometastasis were included with 8 patients excluded due to a RT dose EQD2 10 < 45Gy. 52 patients were in final analysis. Most were men (67%) with a median age 68 years (range, 35-91). Most had bladder primary (79%) with the remaining including upper tract. Majority had pure UC (85%) and the remainder were UC subtypes with variant histology including small cell (8%), squamous (6%), sarcomatoid (2%). Median number of metastases was 1 site, while 23% had 3+ sites. Bony metastases (27%) were most common site, then retroperitoneal nodes (18%) and lung (17%). Most received ≥2 systemic therapy cycles before MDT (62%) with 8% without any therapy prior to MDT. Most commonly used therapy included ddMVAC (21%), Gem/Cis (20%), pembrolizumab (15%), and EV (12%). MDT was delivered to all metastases in 71%, while the remaining had MDT to select sites. Most common MDT dose was 30Gy in 3 fractions (21%) followed by 50Gy in 4 fractions (17%). Median follow up from metastatic diagnosis was 19 months (range, 3-106 months). Median PFS and OS was 21 months (95% CI 8-33 months), and 39 months (95% CI, 14-64 months), respectively. At last follow up, 31 patients were alive (60%). Most common first recurrence was distant from site of MDT (96%) while 2 patients had in-field recurrence in pelvic bones. On univariate analysis, those with 1 vs 2+ sites had improved PFS with MDT (p=0.03, 95% CI 1.1-6.0). Univariate showed no association with MDT to all sites vs select, age, or # lines of systemic therapy. Conclusions: As systemic therapy has improved for patients with bladder and upper tract cancers, MDT may serve as an effective adjunct to improve cancer control. Baseline characteristics. Characteristic (n=52) No % Median Age (yrs) 68 Histology UC 44 85% UC subtype with variant histology 7 15% Site of Primary Bladder 41 79% Upper Tract 11 21% Lines of therapy before MDT 0 4 8% 1 17 33% 2+ 31 60%
Clinicopathological features and prognosis of MED15-TFE3 rearrangement renal cell carcinoma: An updated report.
492 Background: TFE3-rearranged renal cell carcinoma (rRCC) is uncommon, and demonstrates unique heterogenous morphological features and distinct immune characteristics. MED15-TFE3 is a rare gene fusion that usually present as an extensive cystic mass with low malignant potential and is more susceptible to immune check point inhibitor. Identifying the clinical characteristics is crucial for the treatment. Methods: All samples were collected retrospectively from West China Hospital between 8/2011 and 5/2024. Diagnosis of MED15-TFE3 gene fusion was confirmed by RNA sequencing and fluorescence in situ hybridization. Both clinicopathological features and follow-up prognosis information were collected for further analysis. Results: The detailed information of 16 cases were described in the table. The median age was 47.5 years (range, 22 to 70 years). Majority of the cases were female (12/16). All patientes were surgically treated (radical nephrecomy: 8; partial nephrectomy: 7; cytoreductive surgery: 1). At initial diagnosis, most cases (14/16) were localized disease, while two patients had positive regional lymph nodes metastasis, and one patient had distant metastasis. For the patients without distant metastasis (n=15), two patients developed metastasis with disease-free survival of 11.4 and 29.0 months, respectively. As for the pathological features, 14 (87.5%) of the casess presented cystic morphologically, and other two (12.5%) were papillary. Except for one patient with diatant metastasis at initial diagnosis, all patients (15/16) were in G2 by ISUP score. For metastatic patients, 3 received first-line therapy (1 axitinib, 1 axitinib + sintilimab, 1 sunitinib), 2 received second-line therapy (1 axitinib + sintilimab, 1 axitinib + toripalimab), 1 received third-line therapy (axitinib + toripalimab and combined with everolimus). They are still under follow-up. Conclusions: MED15-TFE3rRCC mainly present low-grade cystic renal neoplasm with favorable prognosis. For metastatic MED15-TFE3 rRCC, there is no standard therapy currently. Clinicopathological characteristics and prognosis of 16 MED15-TFE3 rRCC cases. Characteristics Cases Age, median (range), years 47.5 (22, 70) Gender Male 4 Female 12 Morphology Cystic 2 Papillary 14 Tumor size, median (range), cm 5.6 (3.3, 14.0) Nephrectomy Radical 8 Partial 7 Cytoreductive 1 T stage T1 10 T2 3 T3 3 N stage N0 14 N1 2 M stage M0 15 M1 1 ISUP grade 2 15 3 1 Distant metastasis Synchronous 2 Metachronous 2 No 12 Survival status Alive 15 Dead 1
Association of high ctDNA tumor fraction (TF) and detection of clinically significant copy number (CN) losses in liquid biopsies (LBx) from patients with advanced prostate cancer (PCa).
53 Background: Detection of somatic genomic alterations (GA) in LBx is dependent upon the amount of tumor DNA shed, inferred by ctDNA TF. Many clinically actionable GA in PCa are homozygous copy number (CN) losses, which present distinct detection challenges relative to short variant (SV) alterations. BRCA2 CN loss in PCa has been associated with prolonged benefit from PARP inhibitors (PARPi), possibly due to the inability to develop resistance-associated BRCA2 reversion mutations. Methods: Tissue-based FoundationOne CDx (TBx) or blood-based FoundationOneLiquid CDx (LBx) comprehensive genomic profiling (CGP) data from PCa patients was interrogated. We compared GA detection rates in TBx, all LBx (any ctDNA TF), and high-TF (ctDNA TF≥20%) LBx for pathogenic/likely pathogenic SVs and CN losses in 5 clinically relevant genes: BRCA1 , BRCA2 , PTEN , RB1 , and TP53 . We used logistic regression on data from the nationwide de-identified Flatiron Health-Foundation Medicine Clinico-Genomic Database (~280 US cancer clinics, ~800 sites of care) to identify clinical factors predicting high ctDNA TF for optimal CN loss detection. Results: 24,888 TBx and 13,604 LBx were available from patients with predominantly advanced/recurrent PCa. The prevalence of CN losses and SVs in the 5 genes, as detected by TBx, are shown in the Table. >30% of all GA in BRCA2 (36%), PTEN (72%) and RB1 (48%) were CN losses, while losses were rare for BRCA1 (6%) and TP53 (7%). Across all LBx, CN loss rates were lower than in TBx ( BRCA1 0.01 vs 0.05%, BRCA2 1.0 vs 3.0%, PTEN 7.4 vs 24%, RB1 1.4 vs 2.7%, TP53 0.7 vs 2.6%), while SV rates were similar to TBx (not shown). However, high-TF LBx and TBx had similar or higher CN loss rates ( BRCA1 0.06 vs 0.05%, BRCA2 3.3 vs 3.0%, PTEN 28 vs 24%, RB1 5.4 vs 2.7%, TP53 2.9 vs 2.6%), suggesting that high ctDNA TF enables optimal CN detection. Logistic regression linked high alkaline phosphatase, high PSA, and blood draw within 60 days prior to a new therapy with greater likelihood of ctDNA TF≥20% (all P <0.01). Conclusions: Detection of SVs requires only modest ctDNA TF, while CN losses require higher ctDNA TF. High alkaline phosphatase and PSA levels are associated with greater likelihood of ctDNA TF sufficient for CN loss detection. About one-third of men with PCa harboring BRCA2 GA have CN loss, which confers prolonged benefit from PARPi. A validated ctDNA TF is a critical quality indicator, and when low, should prompt consideration of confirmatory TBx to ensure that actionable CN losses are not missed. Gene Rate of homozygous CN loss detection (TBx, %, 95CI) Rate of SV detection (TBx, %) Proportion of all GA due to CN loss (TBx, %) BRCA1 0.05 [0.03-0.09] 0.76 [0.65-0.87] 6.5 [3.5-11] BRCA2 3.0 [2.8-3.2] 5.2 [5.0-5.5] 36 [34-39] PTEN 24 [23-25] 9.0 [8.6-9.4] 72 [71-73] RB1 2.7 [2.5-2.9] 2.9 [2.7-3.1] 48 [45-51] TP53 2.6 [2.4-2.8] 36 [35-37] 6.7 [6.2-7.2]
Complications after transurethral resection of bladder tumor: Findings from the 2022 ACS NSQIP database.
742 Background: Transurethral resection of bladder tumor (TURBT) is a widely utilized procedure for the diagnosis and treatment of bladder cancer (BC). Despite its well-established role, TURBT is associated with a relatively high rate of postprocedural complications. This study aimed to provide an update on the most prevalent complications following TURBT, using data from the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) 2022 database. Methods: The ACS NSQIP 2022 database was queried for all patients who underwent TURBT. Current Procedure Terminology (CPT) codes 52234, 52235, and 52240 were used to identify size-specific TURBTs. Standard statistical analysis using R version 4.4.1 was performed to determine complications. Results: A total of 9,448 TURBTs were included in our analysis. Median age was 73 years old (IQR: 58-88), 2,315 females and 7132 males that received a TURBT within the cohort. Patients with concurrent procedures were removed from the final analyses, but those who received intravesical chemotherapy or underwent concurrent ureteroscopy were retained. The overall complication rate of TURBT was 8.04% in 2022. Postprocedural urinary tract infection (UTI) - within 30 days after TURBT - was the most common complication, accounting for 4.5% of total complications. 160 patients or 1.7% were found with more than one complication. There were no significant differences in complications by age or sex (p = 0.129 and p = 0.124); however larger tumors were related to higher likelihood of post-operative complications. Conclusions: Serious adverse complications after TURBT are rare and TURBTs are generally a safe procedure. However, the ACS NSQIP database suggests that postprocedural UTI are the most common but the rate may be marginally higher than previously reported in TURBT patients. The key limitation of this study was the inability to report the most serious complications of TURBT – i.e. bladder perforation and TUR syndrome – due to NSQIP database’s inability to capture detailed case-specific data. More detailed studies assessing patient-reported outcomes may provide a better method to evaluate the types of complications following TURBT. 30-day complications after TURBT in 2022. 30-day Complications Frequency Percentage Acute Renal Failure 4 0.043% Cardiac Arrest Requiring CPR 10 0.108% Still in Hospital after 30 days 15 0.161% Stroke/CVA 22 0.237% Pneumonia 31 0.333% DVT/PE/Thrombophlebitis 48 0.508% Transfusions Required 122 1.312% Progressive Renal Insufficiency 135 1.452% Related Reoperations within 30 days 148 1.592% Urinary Tract infections 430 4.603% Total 760 8.044%
Racial differences in active surveillance intensity and overtreatment in men with prostate cancer.
316 Background: Marginalized communities in cancer care are often characterized by lower healthcare utilization. In prostate cancer, however, utilization may have mixed effects on quality, particularly in the Medicare population where non-cancer health risks are more prevalent. In this context, we examined racial differences in active surveillance intensity (i.e. confirmatory testing) and potential overtreatment, two key measures of prostate cancer care quality. Methods: Using a 20% national sample of Traditional Medicare beneficiaries, we identified men with newly diagnosed prostate cancer from 2014 to 2019. We used multivariable logistic regression to evaluate the association between race (White, Black, or other) and receipt of a confirmatory test (prostate biopsy, magnetic resonance imaging, or genomic testing) within one year of diagnosis among men on active surveillance. We created a subset of patients with significant comorbidities to assess potential overtreatment (i.e., treatment among patients with >50% estimated non-cancer mortality in five years). Results: We identified 41,092 men meeting inclusion criteria. On adjusted analysis, Black men (OR=0.75; 95%CI: 0.62-0.92, p=0.01) had lower odds of receiving a confirmatory test compared to White men. Among men at risk of overtreatment, Black men (OR=0.86; 95%CI: 0.77-0.97, p=0.01) were less likely to receive treatment compared to White men. Further, all patients, regardless of race, had a predicted probability <50% of receiving a confirmatory test within one year of diagnosis (Table). Conclusions: Our study highlights racial differences in two measures of prostate cancer care, receipt of a confirmatory test and overtreatment. We demonstrated that Black men have lower odds of receiving a confirmatory test. This stands to disproportionately affect Black men, given that they present with higher risk tumors compared to other racial groups. Conversely, Black men have lower odds of being overtreated when compared with White men, suggesting that lower utilization may shield them from potential overtreatment and its related morbidity. As a result, policy efforts aiming to reduce disparities may be most impactful by prioritizing clinical contexts where utilization and access are tightly aligned with care quality. Predicted probabilities for confirmatory testing and overtreatment. White Black Other Confirmatory Testing 43% 37%* 46% Overtreatment 50% 43%* 46%* Adjusted for socioeconomic status tertile, Charlson Comorbidity Index, age, rurality, and year of diagnosis. *Indicates p<0.05.
A phase 2 study of cabozantinib and nivolumab in metastatic castration resistant prostate cancer (CANOPY).
TPS302 Background: Advanced metastatic-castration-resistant prostate cancer (mCRPC) remains a lethal disease with limited treatment options. Cabozantinib is a tyrosine kinase inhibitor (TKI) that targets VEGF, MET and AXL that has demonstrated activity in patients with mCRPC, particularly in individuals with bone and liver metastases. Studies have demonstrated anti-tumor activity of cabozantinib combined with atezolizumab, a programmed death ligand 1 targeting agent. In this study, we will investigate the efficacy of cabozantinib in combination with nivolumab, a programmed death 1 (PD-1) targeting agent, in patients with mCRPC. Methods: This is a prospective, multi-center, single arm, two-stage open label phase II study of cabozantinib combined with nivolumab in the treatment of patients with mCRPC. Eligible patients include those with histologically or cytologic evidence of prostate adenocarcinoma or mixed adenocarcinoma/neuroendocrine tumors, progressive mCRPC disease defined by PCWG3 criteria, exposure to one prior androgen receptor pathway inhibitor (ARPI), and one prior taxane chemotherapy (in hormone sensitive or castration resistant setting). Exclusion criteria include pure small cell carcinoma, received prior immune checkpoint inhibitor, received prior cabozantinib, and received >1 line of chemotherapy (including both hormone sensitive and castration resistant settings). Prior to treatment initiation, patients will receive a mandatory baseline biopsy. Eligible patients will receive treatment with cabozantinib (orally 40 mg daily) and nivolumab (intravenous 480 mg every 4 weeks). An on-treatment biopsy will be performed during cycle 2. Patients will continue on treatment until disease progression, unacceptable toxicity, death, or other reason (e.g., subject withdrawal). The primary endpoint is radiographic progression-free survival (rPFS) at 6 months by RECIST 1.1 for soft tissue and PCWG3 for bone metastasis. Secondary endpoints include PSA response per PCWG3, overall response rate (ORR), and overall survival (OS). For statistical analysis, a Simon’s two-stage MiniMax design will be used with 80% power and one-sided significance level of 5%, hypothesizing that the true 6-month rPFS rate is >30% and assuming the observed rate is 47%. Stage I of the trial will accrue 32 patients and the trial will proceed to stage II if > 9 patients are progression-free and living at 6 months. Stage II of the trial will accrue 18 more patients, and we will conclude that the study treatment is associated with a 6-month PFS rate > 30% if ≥ 21 subjects among 50 enrolled subjects are progression-free and alive at 6 months. This trial is conducted through the Hoosier Cancer Research Network and is actively accruing patients at the University of California San Diego, UT Southwestern, University of Chicago, and University of Wisconsin. Clinical trial information: NCT05502315 .
The estrogen response pathway as a putative predictive biomarker of neoadjuvant pembrolizumab benefit in patients with muscle-invasive bladder carcinoma (MIBC).
843 Background: Sex-specific differences in incidence, stage, and prognosis of have raised interest in the role of sex steroid hormones in pathogenesis and treatment response of MIBC. Emerging evidence supports the involvement of both androgen and estrogen pathways in MIBC. We have previously identified the androgen receptor pathway as a negative predictive biomarker for neoadjuvant immunotherapy (Tateo et al. GU-ASCO24). However, little is known about the role of the estrogen receptor (ER) pathway. Methods: In this unplanned post-hoc analysis of PURE-01 study, we evaluated transcriptome-wide expression with the Decipher assay in 102 transurethral resection of the bladder (TURB) samples of cT2-4N0M0 MIBC patients (pts) treated with neoadjuvant pembrolizumab and radical cystectomy (RC). Here, we focused on ER gene expression and estrogen response signatures (ERS-early and ERS-late), assessing the expression of 200 estrogen pathway-related genes (PMID: 26771021). Moreover, we analyzed the correlation between Immune-190 signature (PMID: 28740126) and ERS-early and -late scores. Pts and tumor characteristics were compared using Wilcoxon rank-sum tests, and Kaplan-Meier analysis assessed the impact of gene expression and signature scores on relapse-free survival (RFS), defined as the time from the first pembrolizumab dose to relapse. Results: From 2017 to 2022, 87 (85.3%) males and 15 (14.7%) females received pembrolizumab and RC. Of note, we did not find significant differences in tumor-based ER gene expression or signature scores between females and males. ER gene expression did not vary across principal molecular subtyping models (TCGA, Consensus, and GSC classifications) although ERS–early and –late pathway activity scores were consistently elevated in luminal tumors. Only ERS-late score differed significantly according to the response to neoadjuvant therapy, showing significantly lower levels in patients who achieved a pathological complete response (p = 0.019). There were no significant differences in RFS based on ER gene expression, while low ERS–early and -late pathway activity scores were significantly associated with better RFS (p = 0.039 and p = 0.009, respectively). Scatter plots revealed a significant, moderate negative correlation between the Immune-190 signature and both ERS-early (cor = -0.64, p = < 0.001) and ERS-late (cor = -0.6, p < 0.001) scores. Conclusions: Estrogen response pathway emerged to be a putative biomarker of immunotherapy benefit in MIBC, with particularly higher scores observed for luminal molecular subtypes, which are related to worse outcomes following neoadjuvant checkpoint inhibition. These findings require further validation in prospective studies and underscore the importance of molecular subtype-driven approaches, potentially facilitating novel combination therapies in MIBC.
Mechanism of action and translation to the clinic of detalimogene voraplasmid (EG-70): A novel, investigational, non-viral immunotherapy for non-muscle-invasive bladder cancer (NMIBC).
826 Background: Detalimogene voraplasmid (EG-70) is a novel, investigational, non-integrating, non-viral gene therapy designed to elicit local stimulation of anti-tumor immune response in the bladder while mitigating the risk of systemic toxicities from immune stimulation. It is administered by intravesical instillation (IVI) to eligible patients with NMIBC to drive bladder-localized expression of innate (RIG-I agonists) and adaptive (IL-12) immune regulators and remodel the tumor microenvironment. LEGEND is an ongoing Phase 1/2 study (NCT04752722) investigating the safety and efficacy of detalimogene voraplasmid in bacillus Calmette Guerin (BCG)-unresponsive NMIBC. We present preclinical data supporting the mechanism of action of detalimogene voraplasmid, which involves immune cell recruitment, tumor microenvironment remodeling and immune training on neoantigens and tumor clearance. Methods: Preclinical evaluation of detalimogene voraplasmid was conducted in vitro in relevant cell lines and in vivo in an orthotopic syngeneic model of bladder cancer in immunocompetent C57BL/6 mice. Luciferase-expressing MB49 cells were instilled in the bladder on Day 1; following confirmation of tumor engraftment by in vivo bioluminescence imaging on Day 9, mice received two weekly IVIs of mEG-70 (a murine surrogate of EG-70) on Days 10&17. Efficacy of mEG-70 was assessed post-dosing by flow cytometry, MSD immunoassays, immunohistochemistry, bioluminescence in vivo imaging, and overall survival. Animal experimentation was approved by the Institutional Animal Care Committee (IACC) and conducted in accordance with Canadian Council on Animal Care (CCAC) guidelines. The Phase 1 component of the LEGEND study evaluated detalimogene voraplasmid in patients with high-risk BCG-unresponsive NMIBC with carcinoma in situ (CIS). Results: Immune profiling revealed remodeling of the tumor microenvironment from an immunosuppressive phenotype to a pro-inflammatory milieu supportive of tumor clearance. Accordingly, administration of mEG-70 was associated with marked reduction in tumor burden and improvement in survival in mice. As demonstrated by either bladder or flank tumor cell rechallenge, the anti-tumor immune response in surviving tumor-free mice resulted in durable protection against subsequent tumor re-challenge, and systemic immune memory. In the Phase 1 part of the LEGEND study, detalimogene voraplasmid was generally well tolerated, with an overall complete response rate of 73% in patients with NMIBC with CIS. Conclusions: These preclinical findings demonstrate that detalimogene voraplasmid delivers genetically encoded immunostimulatory payloads locally to the bladder. The mechanism of action described preclinically has been translated into the clinic in the Phase 1 part of the LEGEND study.
Heterogeneity in subgroup reporting across clinical trials assessing systemic therapies in metastatic castration resistant prostate cancer: A report from a living systematic review.
270 Background: Inconsistent reporting of subgroup data across clinical trials makes interpretation and application of the evidence from trials challenging. We conducted a living systematic review to summarize evidence for American Society of Clinical Oncology (ASCO) guidelines for management of metastatic castration resistant prostate cancer (mCRPC). Here, we provide an overview of reporting patterns of subgroup data across mCRPC trials. Methods: MEDLINE and EMBASE were systematically searched from each database's inception through September 20 th , 2024, to identify phase II/III/IV randomized clinical trials assessing the efficacy and safety of treatment options in mCRPC. For outcomes of overall survival (OS) and progression free survival (PFS), data from the subgroup analyses was collected and compared across trials to assess heterogeneity in the reporting of subgroups. Results: This analysis included 141 trials (phase II: 83; phase III: 56; phase IV: 2). OS was reported by 113 (80%) trials; 32 (28%) reported OS by any subgroups with 95 unique subgroup categories. PFS was reported by 110 (78%) trials; 23 (21%) reported PFS by any subgroups with 63 unique subgroup categories. Even among consistently reported subgroups, such as age, ECOG performance status, race, geographical area, and Gleason score, considerable heterogeneity in different subgroup levels/thresholds was observed across trials. Top ten most commonly reported subgroups are summarized (Table). Conclusions: Lack of consistent reporting for subgroup analysis in mCRPC trials preclude meaningful conclusions about clinically relevant subgroup and synthesizing evidence for clinical guidelines. A standardized framework for consistent reporting of subgroup data across trials can help inform clinical practice and clinical practice guidelines. OS PFS Number of trials 113 110 Reporting subgroup analysis – N (%) 32 (28) 23 (21) Commonly reported subgroups – (N) Age (26)ECOG-PS (26)LDH (21)PSA (18)Geographic area (15)Alkaline phosphatase (14)Visceral disease (14)Gleason score (9)Race (9)Brief pain inventory level (8) Age (21) ECOG-PS (19)PSA (18)LDH (14)Geographic area (13)Visceral disease (11)Gleason score (10)Alkaline phosphatase (9)Bone metastasis (9)Disease location (9) Age – (N) <65 (14); ≥65 (9); ≤68 (1); ≥69 (1); <70 (5); ≥70 (5); ≤74 (4); 65-75 (5); ≤ 71 (1); >71 (1); ≥75 (11); >Median (1); <Median (1) <65 (12); 65-74 (6); ≥65 (6); <70 (5); ≥70 (5); <75 (4); ≥75 (10); 76-80 (1); >80 (1) ECOG-PS – (N) 0 (15); 0-1 (11), 1 (11); 1-2 (5); 2 (12) 0 (15); 0-1 (5), 1 (12); 1-2 (2); 2 (6) Race – (N) White (9)Non-white (6)African American/black (2)Asian (2) White (8)Non-white (5)African American/black (2)Asian (4) Geographic Area – (N) Europe (8)North America (14)United States (1)Australia (1)Asia (2) Europe (11)North America (13)United States (1)Australia (1)Asia (2)North and South America (2) Gleason Score – (N) 2-6 (1); 7 (1); 8 (1); <8 (8); ≥ 8 (8); 9-10 (1) <8 (10); ≥ 8 (10)
Clinicopathological variations between early and late recurrence in bladder cancer post-radical cystectomy.
874 Background: Over 50% of patients diagnosed with muscle-invasive bladder cancer are estimated to experience urothelial cell carcinoma (UCC) recurrence following radical cystectomy (RC). Current studies have found clinicopathological factors associated with overall UCC recurrence; however, there is a lack of data on variations between patients with early versus late recurrence. This study examines the clinicopathological differences of these cohorts. Methods: Within our single institutional IRB-approved cystectomy database, we reviewed 1,050 patients from 1971 - 2023 who underwent RC with intent to cure for primary UCC and experienced recurrence at the University of Southern California. Patients included had documented recurrence via biopsy or imaging. Patients with distant metastasis at RC were excluded. Clinicopathological factors were chosen based on significance in prior studies. Early recurrence (ER) was defined as within two years of cystectomy, the most common time frame for UCC, and late recurrence was beyond two years. Cox regression and chi-squared tests were utilized to compare the groups. Results: Among 1,050 patients, the median age was 68. Of the 928 open cystectomies, 73.2% had ER, compared to 87.7% of the 122 robotic cystectomies. ER rates were 71.9% for the 588 orthotopic diversions, 69.9% for the 143 continent diversions, and 82.5% for the 319 incontinent diversions. Factors predictive of ER included older age (OR = 1.582, p = 0.0017), higher Charlson Comorbidity scores (OR = 1.460, p = 0.0112), higher ASA scores (OR = 1.900, p = 0.001), hydronephrosis prior to RC (OR = 1.944, p = <0.0001), lymphovascular invasion (OR = 1.472, p = 0.0383), lymph node involvement at RC (OR = 2.770, p = <0.0001), neoadjuvant chemotherapy (OR = 3.457, p = <0.0001), incontinent urinary diversions (OR = 1.832, p = 0.0008), greater than pT3 pathological staging (p = <0.0001), and variant histology (OR = 1.782, p = 0.0006). Conclusions: This study identifies clinicopathological risk factors significantly associated with ER. By describing these factors, this study aims to improve predictions of UCC recurrence patterns and inform personalized treatment. Further research is needed to validate our findings and optimize surveillance protocols for at risk patients. Multivariate analysis of variables predictive of early recurrence. Variable Hazard ratio p-value Age > 70 1.464 (1.054 - 2.042) 0.0238 Pre-operative Albumin 0.990 (0.981 - 0.999) 0.0227 Neoadjuvant Chemotherapy 3.527 (2.187 - 5.930) <0.0001 Pathological Staging Organ - Confined Extravesical Lymph Node Positive Ref4.511 (2.955 - 7.024)7.553 (5.000 - 11.636) <0.0001 Urinary Diversion Orthotopic Diversion Continent Diversion Incontinent Diversion Ref0.807 (0.513 - 1.281)1.459 (1.003 - 2.139) 0.0531 Adjuvant Chemotherapy 0.568 (0.372 - 0.863) 0.0083
Association between neutrophil and tumor-infiltrating lymphocyte count and bladder cancer stage and treatment response in BCG-treated mice models.
823 Background: Although Bacillus Calmette-Guérin (BCG) is widely used to treat bladder cancer, its mechanism is still not fully understood. Tumor-infiltrating lymphocytes (TIL) have been postulated to have prognostic value in bladder cancer, where presence of TIL signifies favorable outcomes. TILs play an important role in the tumor immune microenvironment, mediating its response to tumorigenesis and immunotherapeutic drugs. Neutrophils are also key players in the initiation, development and progression of bladder cancer. This study features BCG-treated mice, demonstrating that TIL and neutrophil count in bladder stroma correlates with tumor stage and response to treatment. Methods: Specific pathogen-free C57BL/6 mice were obtained. BBN acquired from TCI America was administered at 0.05% in water, provided ad libitum to half of the cages, while the other half received regular water. BBN administration began at 8-10 weeks of age and continued for 12 weeks. Subsequently, mice received regular water until study completion. Tumors were evaluated via ultrasonography starting at week 14. Upon detecting intravesical tumors, intravesical BCG treatment was given weekly, up to 6 weeks. Bladders were harvested for histopathological analysis, H&E stains were obtained. BCG-treated bladder tumors collected from 85 patients via transurethral resection were similarly analyzed. Results: TILs showed significant association with tumor stage and BCG-treatment response. In BCG-treated mice, mean TIL counts for stages T0 to T4 were 96±13.2 (T0), 11.1±15.1 (T1), 15±4.2 (T2), and 4.1 (T4). Neutrophil count also showed a significant association with tumor stage progression. In BCG-treated mice, the mean neutrophil counts for stages T0 to T4 were 30.25±11.6 (T0), 37.7±18 (T1), 46±34 (T2), 48±25.5 (T3), and 75.5±44 (T4) (p<0.01). We further analyzed the neutrophil to lymphocyte Ratio (NLR) to predict tumor response. Using an optimal threshold of 1.93, NLR was calculated as the ratio of neutrophils to total lymphocytes in the stroma. ROC analysis for predicting poor response to BCG (defined as ≥ T2) yielded an AUC of 0.72, demonstrating a reasonably good predictive ability. Sensitivity was 81.25%, specificity was 87.50%, and overall accuracy was 83.33%. Tumor-infiltrating neutrophil (TIN) count in humans showed a significant association to tumor recurrence, with an OR of 1.25 (p=0.03). Conclusions: In conclusion, this study demonstrates that in a BCG-treated murine bladder cancer model, both the neutrophil count and the NLR are positively correlated with tumor stage. Using NLR to predict poor response to BCG, ROC curve yielded an AUC of 0.72, with a sensitivity of 81.25% and specificity of 87.50%. Additionally, TIL counts were significantly associated with response to BCG treatment. Validation in humans showed a significant association between TIN count and tumor recurrence.
Smooth muscle contractility of laser-enucleated prostate tissues and impacts of preoperative α1-blocker treatment in patients with and without catheterization
Abstract Prostate smooth muscle contraction is central in treatment of voiding symptoms in benign prostatic hyperplasia (BPH). Tissues from transurethral resection of the prostate (TURP) and radical prostatectomy (RP) for prostate cancer are widely used to study contractions. However, findings are limited by traumatization in TURP, and uncertain relationship to BPH in RP tissues. This study aims to examine contractions of laser-enucleated tissues. Tissues from holmium/thulium laser enucleation (HoLEP/ThuLEP) and TURP were contracted by KCl, noradrenaline and electric field stimulation (EFS) in an organ bath. Contractions were compared to RP tissues in previous studies. KCl-induced contractions averaged 2.5 mN, 0.7 mN and 3.3 mN in tissues from HoLEP/ThuLEP, TURP and RP, with non-responsive tissues included (2.4% HoLEP/ThuLEP, 37% TURP). Maximum EFS-induced contractions (Emax) averaged 47% of KCl in HoLEP/ThuLEP tissues, 27% in TURP tissues, and 68–235% in 21 previous studies with RP tissues. Emax values for noradrenaline averaged 99.7% in HoLEP/ThuLEP tissues, 56% in TURP tissues, and ranged from 92 to 260% in RP tissues. Preoperative α1-blocker treatment reduced EFS- and noradrenaline-induced contractions, and increased EC50 values for noradrenaline in laser-enucleated, catheterized patients, but not in patients without catheterization. Also, the ex vivo application of α1-blockers increased the EC50 values for noradrenaline and reduced Emax for EFS. Laser-enucleated tissues allow investigation of prostate smooth muscle contraction in medication-refractory voiding symptoms. Different impacts of preoperative α1-blocker treatment on ex vivo contractility in tissues from patients with and without catheterization point to clinically relevant heterogeneity of patients undergoing surgery for BPH.
The impact of social vulnerability on perceived health in individuals with bladder cancer.
678 Background: Bladder cancer is the sixth most common malignancy in the United States. Social determinants of health (SDOH) have been increasingly recognized as drivers of disparities in cancer care. Improved understanding of the role of social vulnerabilities could better inform the cancer care delivery interventions towards equitable cancer care for bladder cancer patients. We aimed to study the impact of key SDOH measures (everyday discrimination, supportive relationships, neighborhood characteristics, and food and housing security) on the perception of overall health in bladder cancer patients using a publicly available database. Methods: A cross-sectional study was conducted using overall health and SDOH survey data collected by the National Institutes of Health All of Us Research Program from June 2017 to June 2022. Ordinal logistic regression was utilized to assess associations between overall perception of health and each specific SDOH survey domain. All statistical tests were two-sided, and a p-value less than 0.05 was statistically significant; multiplicity adjustments were not made. The Statistical package (0.13.5) of Python (Version 3.1) was used for all statistical analyses. Results: 1,796 participants with bladder cancer met the inclusion criteria. 640 (38.58%) had completed the SDOH surveys and were considered for analysis. Of the total population, there was a significant male preponderance (66.1% vs 31%). 559 (87.3%) were White, 3.4% Black or African American, and 3.6% with Hispanic ethnicity. In the ordinal logistic regression models. for every unit increase in the score of the supportive relationships SDOH domain (more supportive relationships), participants were 4% (OR = 1.04, 95% CI = [1.018, 1.053], p<0.0001) more likely to have a higher perception of general health. Similarly for every unit increase in the food and housing security domain (more secure food and housing status), participants are 19% ((OR =1.19, 95%CI= [1.06,1.34], p 0.004) more likely to have a higher perception of general well-being. Controlling for all other variables, Black race, Hispanic ethnicity, smokers, and age less than 65 years were independently significant for poor perception of overall health (p < 0.05). Conclusions: This is one of the first studies evaluating the role of each component of SDOH on the perception of overall health in bladder cancer patients. Our study demonstrates a clear predictive link between social determinants of health and the perceived overall health of bladder cancer patients. Specifically, stronger social support networks and secure access to food and housing were significantly associated with a more positive perception of health. These findings suggest that future directions in bladder cancer care should prioritize the development and implementation of comprehensive care models that address these social needs.
CHAPTER-Platform-201: Phase 2 trial of pimitespib plus enzalutamide for patients with metastatic castration-resistant prostate cancer.
TPS296 Background: Metastatic castration-resistant prostate cancer (mCRPC) patients (pts), especially those who experience disease progression while on androgen receptor signaling inhibitor (ARSI) therapy, have a poor prognosis and limited treatment options. Although taxanes are an available options, a second ARSI is more frequently used in this setting because of the toxicity of taxanes, pts’ preference, and comorbidities. However, the efficacy of a second ARSI is limited because of cross-resistance. The main mechanisms of cross-resistance are androgen receptor (AR) genomic alterations (AR amplification and mutation), AR splice variants, and upregulation of the glucocorticoid receptor (GR) and components of the PI3K/AKT pathway. Therefore, new treatment options for mCRPC after ARSI therapy are urgently needed. Pimitespib (PIMI) is a novel heat shock protein 90 (HSP90) inhibitor approved for treating Gastrointestinal Stromal Tumor. HSP90 is a molecular chaperone and forms the structure of client proteins. Many of HSP90's client proteins, such as AR and GR, which represent components of the PI3K/AKT pathway, have been identified as prostate cancer-related proteins required for tumor development; their activation depends on HSP90. PIMI suppresses the expression of AR and GR, which are client proteins related to bypass pathways, such as the PI3K/AKT pathway, by inhibiting HSP90 expression; this may help overcome acquired resistance to ARSI. This phase 2 study investigated the efficacy of PIMI in combination with enzalutamide (ENZ) in pts with mCRPC refractory to ARSI. Methods: This phase 2 study was conducted in pts with mCRPC who showed disease progression on one ARSI. The study includes two parts: feasibility part (FP) and expansion part (ExP). The FP is evaluated with six pts to determine the maximum tolerated dose of PIMI (160 mg/day or 120 mg/day, orally; 5 days on/2 days off) in combination with a standard dose of ENZ (160 mg/day, orally; once daily). The ExP is an open-label, randomized trial evaluating the efficacy and safety of a determined dose of PIMI in combination with ENZ versus ENZ monotherapy. Forty pts are randomized 1:1 to each arm. The primary endpoint of FP is dose-limiting toxicity, and ExP is blinded independent central review of radiographic progression-free survival (rPFS). The secondary endpoints include investigator-assessed rPFS, overall survival, objective response rate, pharmacokinetics, and safety. Among pts for whom mCRPC was diagnosed, those with histologically or cytologically confirmed prostate adenocarcinoma and prior refractory status to one ARSI are eligible for enrollment. Pts who had received taxanes for mCRPC are excluded. Enrollment began in July 2023 and is currently ongoing. Clinical trial information: 2031230263 .
Beyond survival: Understanding the social dimensions of prostate cancer.
28 Background: Prostate cancer carries one of the highest burdens of racial disparities in outcomes in oncology. Understanding social determinants of health (SDOH), which measure inequities in healthcare, could give us insight into quality improvement strategies. We aimed to study the impact of key SDOH measures (everyday discrimination, supportive relationships, neighborhood characteristics, and food and housing security) on the perception of overall health in prostate cancer survivors using a publicly available database. Methods: A cross-sectional study was conducted using overall health and SDOH survey data collected by the National Institutes of Health All of Us Research Program from June 2017 to June 2022. Ordinal logistic regression was utilized to assess associations between overall perception of health and each specific SDOH survey domain. All statistical tests were two-sided, and a p-value less than 0.05 was statistically significant; multiplicity adjustments were not made. The Statistical package (0.13.5) of Python (Version 3.1) was used for all statistical analyses. Results: 5,909 male participants with prostate cancer met the inclusion criteria. 2,280 (38.58%) had completed the SDOH surveys and were considered for analysis. Of those, 1,966 (86%) were White, 5.88% Black or African American, and 3.55% Hispanic in ethnicity. In the ordinal logistic regression models, for every unit increase in the SDOH neighborhood characteristics score, the odds of having a higher perception of general health increased by 3% (OR 1.03, 95% CI = [1.02, 1.04], p < 0.0001). For every unit increase in the SDOH day-to-day discrimination score, the odds of having a higher perception of general health increased by 3% (OR 1.03, 95% CI = [1.02, 1.04], p < 0.0001). For every unit increase in the score of the supportive relationships SDOH domain, participants were 4% (OR = 1.04, 95% CI = [1.035, 1.053]) more likely to have a higher perception of general health. Controlling for all other variables, Black race, Hispanic ethnicity, a history of mental health disorders, smokers, and age less than 65 years were independently significant for poor perception of overall health (p < 0.05). Conclusions: While SDOH have been linked with prostate cancer-specific mortality, this is one of the first studies evaluating the role of each component of SDOH on the perception of overall health. We highlighted that factors including neighborhood, discrimination, and supportive relationships have a quantifiable impact on health. Our study provides objective predictive changes in the overall perception of health. Using our variables as a model to predict the effect of changes in these determinants and tailor support to individual needs could ultimately improve quality of life.
Population attributable fraction of dietary risk factors for cancer mortality with a focus on gastrointestinal cancers in a population based cohort study
Abstract Diet and nutrition are critical factors influencing cancer, the second leading cause of death worldwide. This study evaluated dietary risk factors and cancer mortality. 49,773 participants aged 40–75 years from the Golestan Cohort Study (GCS) were followed for a median of 15 years. Dietary intake was assessed using a validated food frequency questionnaire. Cox proportional hazard models estimated hazard ratios (HRs) and 95% confidence intervals (CIs), while population attributable fractions (PAFs) quantified the impact of reducing dietary risk factors. Low fruit intake accounted for 4.7% (95% CI: 0.5-8.7%) of all cancer deaths and 4.91% (95% CI: 0-9.85%) of male cancer deaths. It contributed to 23.5% (95% CI: 4.7-38.59%) of pancreatic cancer mortality in both sexes and 29.36% (95% CI: 5.15-47.38%) of male pancreatic cancer deaths. Low omega-3 intake increased esophageal and gastric cancer mortality risks, with PAFs of 21.65% (95% CI: 1.14-37.9%) and 21.46% (95% CI: 2.81-36.53%), respectively. In females, low omega-3 intake accounted for 38.68% (95% CI: 4.05-60.81%) of gastric cancer deaths. Low fruit and omega-3 consumption elevated cancer mortality risk. Community- and individual-level interventions are essential to enhance nutrient intake and reduce cancer mortality.
Multicenter analysis of high-dose chemotherapy (HDCT) regimens for recurrent germ cell tumors (GCTs).
631 Background: HDCT is an established salvage treatment for patients (pts) with recurrent germ cell tumors (GCTs). However, comparative analyses between contemporary HDCT approaches are lacking. This study presents an updated, multi-center analysis of the two most commonly used HDCT regimens: 1) Carboplatin 700 mg/m² and etoposide 750 mg/m² (CE) for two cycles, and 2) Carboplatin AUC 7-8 and etoposide 400 mg/m² for three cycles following two cycles of paclitaxel 200 mg/m² and ifosfamide 2000 mg/m² (TICE). We also included less common high-dose carboplatin-based regimens. Methods: Data from four high-volume referral centers were pooled and included pts treated with HDCT for recurrent GCTs between 1/1/2010 and 1/1/2024. Pts received either CE, TICE, or other regimens, though formal comparisons focused on the CE and TICE cohorts. Statistical tests used included Fisher’s exact test and Wilcoxon rank-sum test for qualitative and quantitative variables, respectively. Kaplan-Meier and log-rank tests were used to estimate and compare relapse-free survival (RFS) and overall survival (OS). Analyses were conducted using R Statistical Software, version 4.3.1. Results: A total of 111 pts were included: 50 received CE (45%), 32 received TICE (29%), and 29 received other high-dose carboplatin-based regimens (26%). Median age at diagnosis was 28.5 years (range 14-58), with the majority being Hispanic (56.8%) and having non-seminomatous GCT (76.6%). Six (12%) and four (12.5%) pts in the CE and TICE cohorts, respectively, had primary mediastinal disease. Late relapses, defined as disease recurrence occurring more than 2 years after first-line treatment, were rare, affecting 1 pt (3%) from the CE cohort and 3 pts (6%) in the TICE cohort. Most pts (43.2%) had International Germ Cell Cancer Collaborative Group poor risk disease at diagnosis. HDCT was administered as second-line therapy in 47.7% of patients and as third-line or beyond in 51.4%, with comparable distribution between TICE (53.1%) and CE (46%). patients receiving transplant as third-line (p=0.459). After a median follow-up of 55.5 months post-transplant, no significant difference in median RFS was observed between TICE and CE (10.2 vs 5.9 months; HR 0.91, 95% CI [0.54, 1.51], p = 0.706). There was a trend toward improved median OS for TICE compared to CE (57.2 vs 19.8 months; HR 0.67, 95% CI [0.37, 1.2], p = 0.18). Previously published prognostic scores using the Beyer, Einhorn, and International Prognostic Factor Study Group models accurately stratified pts by RFS and OS. Subgroup analysis suggested a possible benefit of TICE over CE in higher-risk patients. Conclusions: This multicenter analysis found no significant difference in RFS between the CE and TICE regimens though a trend toward improved OS with TICE was observed, particularly in pts with higher-risk disease.
Prospective observational study in Japanese patients with metastatic castration-sensitive prostate cancer (mCSPC) with or without intraductal carcinoma of the prostate (IDC-P).
87 Background: Intraductal carcinoma of the prostate (IDC-P) is a high-grade, high-volume, invasive form of prostate cancer (PCa) associated with poor clinical outcomes. The International Society of Urological Pathologists (ISUP) recommends incorporating IDC-P into the Gleason scoring system. However, existing data on survival outcomes for prostate cancer patients with IDC-P are primarily based on retrospective analyses. This study aims to prospectively evaluate the survival outcomes of Japanese patients with metastatic castration-sensitive prostate cancer (mCSPC), with and without IDC-P, using real-world data from a multi-institutional observational study. Methods: Between 2018 and 2021, we prospectively enrolled 102 de novo mCSPC patients from affiliated healthcare institutions. Eligible patients were those diagnosed with mCSPC via prostate needle biopsy and classified as high-risk according to the LATITUDE criteria. All participants underwent a standard extended biopsy (≥10 cores) to diagnose IDC-P, ensuring minimal sampling error. A single genitourinary pathologist reviewed all biopsy slides based on the 2019 ISUP grading system. Patients received treatment with androgen receptor signaling inhibitors (ARSI) with or without docetaxel. Results: The median age of the patients was 72 years (range 57–92), and the median serum PSA level was 441 ng/mL (range 3.9–9807 ng/mL). The median follow-up period was 38.3 months (range 8.2–67.4 months). All patients had a Gleason grade ≥ 3, with 66 (64.7%) exhibiting a Gleason pattern 5. Lymph node metastasis was present in 67 patients (65.7%), visceral metastasis in 23, and bone metastasis in all patients. IDC-P was identified in 86 patients (84%). Multivariate analysis revealed that elevated lactate dehydrogenase (LDH) levels and the presence of IDC-P were independent predictors of poor castration-resistant prostate cancer (CRPC)-free survival (HR 4.387, p<0.001; HR 2.009, p=0.01) and progression-free survival (PFS2) (HR 6.801, p<0.001; HR 1.796, p=0.016). Conclusions: This prospective observational study demonstrated that higher LDH levels and the presence of IDC-P in biopsy samples were significantly associated with poorer survival outcomes in Japanese patients with mCSPC. These findings underscore the prognostic importance of IDC-P in mCSPC management.
Evaluating cost-effectiveness in the evolving treatment landscape for metastatic urothelial carcinoma.
695 Background: Metastatic urothelial carcinoma (mUCa) is the most expensive cancer to treat on a per-patient basis, largely due to the need for frequent interventions and costly follow-up care. In examining first-line therapies, combinations such as enfortumab-vedotin plus pembrolizumab (EV + P) and gemcitabine/cisplatin plus nivolumab show substantial overall survival advantages over the standard treatment (SoC) of gemcitabine/cisplatin. This study presents a cost-effectiveness analysis for mUCa. Methods: We developed a Markov model from a payer's perspective, utilizing clinical data derived from the Phase III Checkmate-901 and EV302/Keynote-A39 trials. To identify the optimal treatment from a socioeconomic standpoint, we employed Monte Carlo simulation, focusing on Germany and the United States (US). Subsequently, we compared the incremental cost-effectiveness ratio (ICER) for each treatment modality across various willingness-to-pay (WTP) thresholds. Results: At a lifetime horizon, SoC, gemcitabine/cisplatin plus nivolumab and EV + P were associated with average costs of €163,424 (US: $458,006), €206,853 (US: $597,802), and €401,170 (US: $1,228,455), respectively, while achieving QALYs of 1.21, 1.71, and 2.31, respectively. The ICERs for the newer treatment strategies were €87,340 (US: $281,142) for gemcitabine/cisplatin plus nivolumab and €216,140 (US: $700,448) for EV + P. At a commonly accepted WTP threshold of €/$100,000, gemcitabine/cisplatin plus nivolumab emerged as the optimal strategy in Germany, while EV + P would necessitate a price reduction of 46% (US: 82%) to achieve cost-effectiveness. Conclusions: QALYs nearly double with the combination of EV + P compared to the current SoC; however, the associated costs may not be justifiable from a strict socioeconomic perspective. Despite offering lower oncological benefits, gemcitabine/cisplatin plus nivolumab should be considered for first-line therapy due to its favorable cost-effectiveness, particularly in Europe. Furthermore, identifying individual risk factors is crucial for optimizing therapeutic responses and managing treatment costs in the future.